{"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"Pembrolizumab: 200 mg IV dose given on day 1 of a three week cycle\n\nRituximab: 375 mg/m2 IV dose given up to 8 times in the trial","id":"BG000","title":"Pembrolizumab and Rituximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"64.5","upperLimit":"76.1","value":"70.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"ECOG 0"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"ECOG 1"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"ECOG 2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}]}],"description":"ECOG Performance Status\n\n0: Fully active, able to carry on all pre-disease performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours\n3. Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair\n5. Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}]}